We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Federal Circuit Court of Appeals gave Amgen another chance to prove that Amneal’s planned generic of its hyperparathyroidism treatment Sensipar (cinacalcet) infringes on its patent. Read More
The study’s authors “erroneously state that FDA abandoned efforts to evaluate the impact of the ER/long-acting REMS program on prescriber behavior and patient outcomes,” the agency said. Read More
Allergan and Ironwood Pharmaceuticals reached a settlement with Sandoz to resolve patent litigation over Sandoz’s planned generic versions of their co-developed irritable bowel syndrome treatment Linzess. Read More
The drug was originally approved in October 2017 as the first extended-release intra-articular therapy for patients with osteoarthritis-related knee pain. Read More